Myriad Genetics To Collaborate With BeiGene - Quick Facts

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced it has entered into a companion diagnostic development collaboration with BeiGene, a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer. BeiGene will use Myriad's myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the clinical development of its PARP inhibitor, BGB-290.

BRACAnalysis CDx is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens. Myriad's myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks.